AMR network CARB-X expands reach
The global antibacterial innovation network CARB-X has expanded its reach by adding six new life-science organisations to its fight against antimicrobial resistance (AMR).
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1997 entries already.
Entries by Thomas Gabrielczyk
Roche swallows Spark Therapeutics in $4.3bn deal
Swiss pharma giant Roche has complemented its drug pipeline in the lucrative hemophilia A market by taking over hemophilia A gene therapy developer Spark Therapeutics for US$4.3bn.
How salt triggers allergy
Sodium chloride can promote immune responses that have been linked to atopic dermatitis. Researchers have now unraveled the mechanistic details between salt intake and activation of T cells.
Calypso Biotech cash in €20M Series A financing
Dutch autoimmunity specialist Calypso Biotech BV has raised €20m in a Series A financing co-led by Gilde Healthcare and Inkef Capital and co-financed by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and the companys seed investor M Ventures.
Evotec and HZI join forces in antibiotics discovery
Evotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in order to find novel resistance-breaking antibiotics against Gram-negative bugs.
First immunotolerant allogenic cell transplants revealed
Researchers for the first time have found a way to prevent immune rejection of allogenic iPSC-derived cell and tissue transplants.
Digital solutions to serialisation
Its only been nine years since the first blockchain technology applications in finance were introduced. Big players are now working to use distributed computing to protect pharma logistics from counterfeit drugs. Unlike current Internet-based solutions, the decentralised blockchain network is immune to manipulation or hacks, as transactions can be verified, recorded, and coordinated autonomously without third-party involvement.
Arvelle Therapeutics raises $180m in Series A financing
Swiss newco Arvelle Therapeutics has baged a $180m (€159.1m) series A financing led by LSP. The company licenced the anti-epileptic candidate cenobamate (YKP3089) for $100m (€88.4m) upfront from SK Biopharmaceuticals.
Bio-plastics production grows to 7.5 million tonnes
The market for bio-based building blocks and polymers showed moderate growth to 7.5 million tonnes in 2018 and will grow with a CGAR of 4% by 2023 reports German nova-Institute.
Reprogrammed pancreatic cells cure type I diabetes
Swiss researchers have demonstrated a way to cure type I diabetes without cell transplantation. In model mice the reprogrammed non-islet cells from human pancreas